A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

Clinical trial NCT02149524 · COMPLETED

Trial details

NCT number: NCT02149524
Sponsor: Samsung Bioepis Co., Ltd.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

HER2 Positive Early or Locally Advanced Breast Cancer

Start date: 2014-04-01
Primary completion: 2016-03-01
Enrollment: 875

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.